PRPOHealthcare · Diagnostics & ResearchTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 4 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Precipio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (83): Smaller than most of the companies we track.
Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PRPO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Nov 2020 | Maxim Group | Initiates | Buy | — |
| 22 Nov 2019 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PRPO appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Precipio, Inc. returned −2.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 64% of US stocks
Cheaper than 39% of US stocks
Cheaper than 98% of US stocks
Higher than 73% of US stocks
Higher than 63% of US stocks
Higher than 55% of US stocks
Higher than 25% of US stocks
Higher than 24% of US stocks
Higher than 37% of US stocks
Higher than 32% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Precipio, Inc. has a market value of $33.3M and an enterprise value of $33.8M.
Revenue in the twelve months to 30 June 2026: $27.2M. The latest quarter grew 24.2% year on year.
Net income over the same four quarters: −$1.2M, a −4.5% net margin.
Free cash flow in the twelve months to 30 June 2026: $789K.
Trailing P/E: −81.9×; forward P/E: 47.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Precipio, Inc. employs 61 people — $446K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Precipio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Precipio announced it will host its Q3-2026 shareholder update call on November 10, 2026, at 5:00 p.m. ET.
Why it matters — The call is an opportunity for PRPO shareholders and other company watchers to receive a quarterly update.
Precipio, a cancer-diagnostics laboratory services provider, has introduced an on-site testing model and is using distributors to reach new clients. Officers and directors hold 16.6% of shares; Vanguard established an initial position, and BlackRock increased its position in Q1 2026.
Why it matters — The item highlights Precipio’s expansion approach and reported institutional and insider ownership as context for PRPO watchers.
Zacks Investment Research published a comparison of Precipio (PRPO) and Fulgent Genetics (FLGT), examining differences in business scope, valuation, and growth drivers to assess which cancer diagnostics stock is more compelling at this time.
Why it matters — A PRPO watcher would care because the piece offers an analytical benchmark of Precipio against a peer in the cancer diagnostics space.
A Zacks Investment Research article compares Precipio and Biodesix, two cancer diagnostics companies with different approaches, examining which stock looks more compelling at this time.
Why it matters — A PRPO watcher would care because the piece directly evaluates Precipio against a peer in cancer diagnostics, offering a comparative view of the company.
Precipio reported second-quarter 2026 results showing strengthened revenue momentum, driven by higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation. The company's stock gained following the earnings announcement.
Why it matters — The report points to sustained revenue growth, record product sales, and improved profitability metrics, which indicate the company's momentum continued into its second quarter.
Of the 1 analysts covering Precipio, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Precipio, Inc. 46 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Precipio, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).
No analyst covering Precipio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRPO are extrapolating price history, which says nothing about the business.
Precipio, Inc. returned -2.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Precipio Inc. is a healthcare biotechnology company focused on cancer diagnostics, with a particular emphasis on hematologic malignancies and laboratory error reduction.
The most recent item we track (GlobeNewsWire, 28 Oct 2026): "Precipio Announces Q3-2026 Shareholder Update Call". Precipio announced it will host its Q3-2026 shareholder update call on November 10, 2026, at 5:00 p.m. ET.
Precipio Inc. is a healthcare biotechnology company focused on cancer diagnostics, with a particular emphasis on hematologic malignancies and laboratory error reduction. The company provides specialized diagnostic services for blood cancers and develops proprietary products used by pathology laboratories, including genetic panels, cell culture media, and related assay technologies. Its business is organized around diagnostic services and diagnostic products, creating an integrated platform that supports testing, workflow efficiency, and clinical decision-making. Precipio Inc. also serves biopharma customers through biomarker testing and clinical project services. Based in New Haven, Connecticut, the company operates in the clinical diagnostics and life sciences markets, where it aims to improve the accuracy and utility of cancer testing for physicians, laboratories, and patients.
CEO Mr. Ilan Danieli · 61 employees · United States · https://www.precipiodx.com
